The US Patent and Trademark Office (USPTO) has issued the US patent covering Cerecor's antitussive, FP01, a unique formulation of memantine hydrochloride. The patent protects composition of lozenge, which provides a dual mechanism of ...
Tags: FP01 Antitussive, USPTO
Neuroscience biotech company Cerecor has acquired exclusive, worldwide rights to develop and commercialize MK-0657 from Merck, referred to MSD outside the US and Canada. The small molecule NMDA receptor subunit 2B antagonist MK-0657 will ...
Tags: Cerecor, Global Development Rights, MK-0657